UPDATE : Monday, September 7, 2020
상단여백
HOME Device/ICT
Celltrion launches 2 Covid-19 diagnostic kits in US
  • By Lee Han-soo
  • Published 2020.08.12 14:49
  • Updated 2020.08.13 16:34
  • comments 0

Celltrion said that it has launched two diagnostic kits of Covid-19 -- Sampinute COVID-19 Antigen MIA and DiaTrust COVID-19 IgG/IgM Rapid Test -- in the U.S.

Celltrion has recently launched two Covid-19 diagnostic kits, Sampinute COVID-19 Antigen MIA (left) and DiaTrust COVID-19 IgG/IgM Rapid Test, in the U.S. (Celltrion)

The company has actively collaborated with specialized companies since February to commercialize diagnostic kits that can meet global market demand and recently completed developing the products.

Sampinute COVID-19 Antigen MIA is a point-of-care testing (POCT) kit for the detection of Covid-19 antigen from nasopharyngeal swab samples in collaboration with BBB. The equipment is composed of a one-time-use test cartridge and a portable analyzer. It takes about 10 minutes for the user to confirm their results.

According to the company, the device also has a higher sensitivity than reverse the transcription-polymerase chain reaction (RT-PCR) test kits.

DiaTrust COVID-19 IgG/IgM Rapid Test is a one-step antibody rapid diagnostic test (RDT) developed in collaboration with Humasis. The device is based on an immunochromatographic assay designed for the rapid detection of Covid-19 antibodies.

"Antibody RDT can test a large number of patients at a low cost easily," the company said. "We believe it can play a complementary role with antigen POCT, and plans to sell the two products in a bundled package to maximize marketability."

Celltrion is also working with Humasis to develop improved antibody and antigen RDT with higher sensitivity.

"By working with promising Korean companies to develop a Covid-19 diagnostic kit, the company has managed to enter into the world's largest medical market," a company official said. "We hope we will help put an end to the pandemic in the U.S. through our quality products."

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top